semaglutide and blindness A new study suggests patients taking — the active ingredient in Ozempic Wegovy — may be at higher risk of developing an eye condition that can cause blindness. Non-arteritic anterior Ozempic Blindness Lawsuit [2026 Guide]

What sets semaglutide apart from some traditional PCOS treatments is its broader focus

Other GLP1 R agonists have been studied in PD and are reviewed elsewhere [35]

Hedges g adjusts the effect size calculations for small samples with fewer than 20 participants, unlike Cohens d (Lakens, 2013)

nevertheless, the mechanism by which it works has yet to be elucidated

There are currently 5-10 million people on a branded GLP-1 medication, but there is an estimated 50-60 million who are clinically eligible to receive Wegovy and have insurance coverage for it, and of those, millions could purchase it for a copay of less than $100/month